Navigation Links
Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection
Date:4/11/2008

(average CMI = 438 ng/mL ATP) than the average measure among patients showing no signs of rejection (average CMI = 301 ng/mL ATP; p = 0.05).

The analysis also looked at the incidence of infections among the study population. A total of 30 infections were identified in patients with low CMI (<225 ng/mL ATP; based on 57 assays) as compared to only eight infections in patients with moderate or strong CMI (>225 ng/mL ATP; based on 113 assays). The average CMI in samples from patients with infection was 119 ng/mL ATP as compared to 336 ng/mL ATP in samples from patients with no sign of infection (p < 0.001). Identified infections included 13 with a viral etiology; 15 with bacterial etiology; and 10 with fungal etiology.

"Immune function monitoring of adult heart transplant patients using the ImmuKnow assay may have the potential to aid in the assessment of the immune status of the patient and the patient's risk for organ rejection or infection," concluded Dr. Kobashigawa. "We are currently conducting clinical studies using these data to manage immunosuppression in our heart transplant patients, with the goal of limiting risk for rejection and infection."

Dr. Kobashigawa's presentation was entitled, "Success of immune monitoring with ImmuKnow (Cylex(TM)) to assess rejection/infectious risk in heart transplantation." Dr. Kobashigawa is Clinical Professor of Medicine and Chief of the Division of Clinical Faculty Medicine at David Geffen School of Medicine at UCLA. He is also Medical Director of the UCLA Heart Transplant Program.

About ImmuKnow(R)

ImmuKnow is an immune cell function assay that can detect cell-mediated immunity (CMI) in adult immunosuppressed patients by measuring the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation.

The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of ImmuKnow assays should be used in conjunc
'/>"/>

SOURCE Cylex Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
2. Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
3. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
4. Seneca Valley High School Student Receives Science Award From MedImmune
5. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
6. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
7. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
8. Immune system protein starves staph bacteria
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. MedImmune Submits Biologics License Application to FDA for Motavizumab
11. Peptimmune Announces First Close of Series D Private Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- AmnioChor Inc., an early stage biotech startup based on ... that the Musculoskeletal Transplant Foundation of Edison ... seed round of development of the proprietary AmnioCept™ product ... AmnioChor,s technology allows cryopreservation of the amniotic membrane ... within those tissues. Amnion is a well-established source of ...
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE MKT: ... results will be released on Thursday, August 13, 2015, ... Time, Pfenex management will host a conference call to ... A press release outlining the financial results and business ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) ...
(Date:7/29/2015)... ... 29, 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers ... drug/device combinations. The current system received a score of 0 (range -10 to +10) ... (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... 1, 2011 Investor Uprising ( www.investoruprising.com ) has ... guide to the best biotech Exchange Traded Funds (ETFs) ... users of the Website. (Logo: http://photos.prnewswire.com/prnh/20110411/NY80781LOGO-a) ... ongoing biotech bull market, identifying the leading biotech mutual ...
... June 1, 2011 Aaron Mitchell, managing principal at global ... top 25 consultants of 2011 by Consulting Magazine. Mitchell was ... biotech firm over several years and during a major, recent ... one of the top consultants," said Mitchell, who has more ...
... June 1, 2011 Reportlinker.com announces that ... in its catalogue: Osteosarcoma ... to 2017 http://www.reportlinker.com/p0546797/Osteosarcoma-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... Assessment and Market Forecasts to 2017 ...
Cached Biology Technology:Investor Uprising Publishes Free Biotech Investment Report 2Investor Uprising Publishes Free Biotech Investment Report 3Managing Principal at ZS Associates Named One of Consulting Magazine's Top 25 Consultants of 2011 2Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 9Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 10
(Date:7/21/2015)... 21, 2015 Passwords have proven futile ... the recent U.S. Office of Personnel Management breach. ... infosec conundrum, but developers and end-users are concerned ... this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today ... for third party integration. A ...
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... list of 235 planthoppers from Iran is recorded along with ... Iranian Auchenorrhyncha during last 100 years. In addition to the ... transferring one species at family level is proposed. The study ... . Planthoppers are studied relatively little, but are ...
... on Centers for Disease Control and Prevention and other ... 30 years, we recognize the importance of reaching our ... with teachers having to incorporate more and more learning ... leave room for nutrition education in elementary schools? ...
... antibody developed by MassBiologics of the University of Massachusetts ... C virus (HCV) infection undergoing liver transplantation significantly suppressed ... and delayed the time to viral rebound. Results from ... this week at The Liver Meeting, the annual meeting ...
Cached Biology News:Cooking in the classroom to fight childhood obesity 2Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients 2Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients 3
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
Homo sapiens postsynaptic protein CRIPT Antigen: Recombinant Protein...
Immunogen: Synthetic peptide based on the sequence: SPSSGPSLTADSMWR Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Biology Products: